An astaxanthin composition and its application

Abstract

The present invention relates to the field of biomedical technologies, and discloses an astaxanthin composition and its application. The astaxanthin composition comprises the following components in parts by mass: 200 - 280 parts of astaxanthin oil, 40 - 60 parts of gardenia extract, 25 - 35 parts of turmeric extract, and 62 - 84 parts of purslane extract; the mass fraction of astaxanthin in the astaxanthin oil is 5%. The astaxanthin composition provided by the present invention can be used for preparing a drug for preventing and treating vaginitis and cervicitis.

Description

Technical Field

[0001] The present invention relates to the field of biomedical technologies, and particularly to an astaxanthin composition and its application. Background Art

[0002] Astaxanthin is a potent natural carotenoid, known to have antioxidant, anti-inflammatory and immunomodulatory effects, and is often used in health foods and functional foods.

[0003] Vaginitis and cervicitis are common gynecological diseases, which are divided into infectious and non-infectious inflammations according to whether they are infected by microorganisms. Clinically, there are often symptoms such as increased vaginal discharge, itching, burning sensation, pain, frequent urination and urgency, vaginal bleeding, etc. Generally, the treatment time is long and it is easy to relapse.

[0004] When the inventors of the present application were developing astaxanthin-related products, they found that a composition prepared by combining astaxanthin with gardenia extract, turmeric extract and purslane extract through related processes can be used to prevent and treat vaginitis and cervicitis. Summary of the Invention

[0005] The present invention provides an astaxanthin composition and its application in the preparation of drugs for preventing and treating vaginitis and cervicitis.

[0006] To achieve the above object, in the first aspect of the present invention, an astaxanthin composition is provided. The composition comprises the following components in parts by mass: 200 - 280 parts of astaxanthin oil, 40 - 60 parts of gardenia extract, 25 - 35 parts of turmeric extract, 62 - 84 parts of purslane extract; the mass fraction of astaxanthin in the astaxanthin oil is 5%.

[0007] Further, the composition comprises the following components in parts by mass: 240 parts of astaxanthin oil, 50 parts of gardenia extract, 30 parts of turmeric extract, 73 parts of purslane extract.

[0008] Further, the composition comprises the following components in parts by mass: 200 parts of astaxanthin oil, 40 parts of gardenia extract, 25 parts of turmeric extract, 62 parts of purslane extract.

[0009] Further, the composition comprises the following components in parts by mass: 280 parts of astaxanthin oil, 60 parts of gardenia extract, 35 parts of turmeric extract, 84 parts of purslane extract.

[0010] In the second aspect of the present invention, a preparation method of the above astaxanthin composition is provided, comprising the following steps:

[0011] S1, adding 25 - 30 parts of glycerol monocaprylate to the astaxanthin oil and stirring to emulsify it to obtain an astaxanthin oil emulsion;

[0012] S2. Add 45 - 130 parts of sodium carboxymethylcellulose and 35 - 55 parts of β - cyclodextrin to the astaxanthin oil emulsion, and stir evenly to obtain a mixed slurry.

[0013] S3. Spray - dry the mixed slurry obtained in step S2 to obtain astaxanthin powder.

[0014] S4. Add the gardenia extract, turmeric extract, purslane extract and the remaining 65 - 110 parts of β - cyclodextrin to an appropriate amount of purified water, stir and dissolve, and then spray - dry the mixture to obtain a mixed powder.

[0015] S5. Mix the astaxanthin powder obtained in step S3 and the mixed powder obtained in step S4 evenly to obtain the composition.

[0016] The third aspect of the present invention provides the application of the above - mentioned astaxanthin composition in the preparation of drugs for preventing and treating vaginitis and cervicitis.

[0017] Through the above - mentioned technical solutions, the present invention can at least achieve the following beneficial effects: The astaxanthin composition of the present invention can be used to prepare drugs for preventing and treating vaginitis and cervicitis. Detailed Embodiments

[0018] In the ranges disclosed herein, the endpoints and any values are not limited to the exact ranges or values. These ranges or values should be understood to include values close to these ranges or values. For numerical ranges, between the endpoint values of each range, between the endpoint values of each range and individual point values, and between individual point values, they can be combined with each other to obtain one or more new numerical ranges, and these numerical ranges should be regarded as specifically disclosed herein.

[0019] In the present invention, the astaxanthin oil and purified water are prepared by our company (Yunnan Green A Bio - engineering Co., Ltd.). The astaxanthin oil is extracted from Haematococcus pluvialis, and the astaxanthin content is 5%.

[0020] In the present invention, the gardenia extract is purchased from Shanyang Lianfeng Biotechnology Co., Ltd., and it is an aqueous extract with a specification of 20:1 (i.e., 20 parts by weight of gardenia fruits are extracted with water to obtain 1 part by weight of gardenia extract).

[0021] In the present invention, the turmeric extract is purchased from Shanyang Lianfeng Biotechnology Co., Ltd., and it is an aqueous extract with a specification of 20:1

[0022] In the present invention, the purslane extract is purchased from Shanyang Lianfeng Biotechnology Co., Ltd., and it is an aqueous extract with a specification of 20:1

[0023] In the present invention, glycerol monocaprylate is purchased from Hebei Hongtao Bio - engineering Co., Ltd.

[0024] In the present invention, β-cyclodextrin was purchased from Chongqing 900 Biotechnology Co., Ltd.;

[0025] In the present invention, sodium carboxymethyl cellulose was purchased from Hebei Pengyu Biotechnology Co., Ltd. Example 1

[0026] An astaxanthin composition, the composition comprising the following components in parts by mass: 240 parts of astaxanthin oil, 50 parts of gardenia extract, 30 parts of turmeric extract, and 73 parts of purslane extract.

[0027] The preparation method of the above astaxanthin composition comprises the following steps:

[0028] S1, adding 87 parts of glycerol monocaprylate to the astaxanthin oil and stirring to emulsify it to obtain an astaxanthin oil emulsion;

[0029] S2, adding 87 parts of sodium carboxymethyl cellulose and 40 parts of β-cyclodextrin to the astaxanthin oil emulsion and stirring evenly to obtain a mixed slurry;

[0030] S3, spray-drying the mixed slurry obtained in step S2 to obtain astaxanthin powder;

[0031] S4, adding the gardenia extract, turmeric extract, purslane extract and 85 parts of β-cyclodextrin to an appropriate amount of purified water, stirring to dissolve, and then spray-drying the mixed solution to obtain a mixed powder;

[0032] S5, mixing the astaxanthin powder obtained in step S3 and the mixed powder obtained in step S4 evenly to obtain the composition. Example 2

[0033] An astaxanthin composition, the composition comprising the following components in parts by mass: 200 parts of astaxanthin oil, 40 parts of gardenia extract, 25 parts of turmeric extract, and 62 parts of purslane extract.

[0034] The preparation method of the above astaxanthin composition comprises the following steps:

[0035] S1, adding 25 parts of glycerol monocaprylate to the astaxanthin oil and stirring to emulsify it to obtain an astaxanthin oil emulsion;

[0036] S2, adding 45 parts of sodium carboxymethyl cellulose and 35 parts of β-cyclodextrin to the astaxanthin oil emulsion and stirring evenly to obtain a mixed slurry;

[0037] S3, spray-drying the mixed slurry obtained in step S2 to obtain astaxanthin powder;

[0038] S4. Add 65 parts of gardenia extract, turmeric extract, purslane extract and β-cyclodextrin to an appropriate amount of purified water, stir to dissolve, and then spray-dry the mixture to obtain a mixed powder.

[0039] S5. Mix the astaxanthin powder obtained in step S3 and the mixed powder obtained in step S4 evenly to obtain the composition. Example 3

[0040] An astaxanthin composition, the composition comprising the following components in parts by mass: 280 parts of astaxanthin oil, 60 parts of gardenia extract, 35 parts of turmeric extract, and 84 parts of purslane extract.

[0041] The preparation method of the above astaxanthin composition comprises the following steps:

[0042] S1. Add 30 parts of glycerol monooctanoate to the astaxanthin oil, stir to emulsify it to obtain an astaxanthin oil emulsion.

[0043] S2. Add 130 parts of sodium carboxymethylcellulose and 55 parts of β-cyclodextrin to the astaxanthin oil emulsion, stir evenly to obtain a mixed slurry.

[0044] S3. Spray-dry the mixed slurry obtained in step S2 to obtain astaxanthin powder.

[0045] S4. Add the gardenia extract, turmeric extract, purslane extract and the remaining 100 parts of β-cyclodextrin to an appropriate amount of purified water, stir to dissolve, and then spray-dry the mixture to obtain a mixed powder.

[0046] S5. Mix the astaxanthin powder obtained in step S3 and the mixed powder obtained in step S4 evenly to obtain the composition.

[0047] Comparative Example 1

[0048] The difference between Comparative Example 1 and Example 1 is that it does not contain gardenia extract.

[0049] Comparative Example 2

[0050] The difference between Comparative Example 2 and Example 1 is that it does not contain turmeric extract.

[0051] Comparative Example 3

[0052] The difference between Comparative Example 3 and Example 1 is that it does not contain purslane extract.

[0053] Comparative Example 4

[0054] The difference between Comparative Example 4 and Example 1 is that it does not contain gardenia extract, turmeric extract, and purslane extract.

[0055] Female rats were provided by the Animal Center of Sun Yat-sen University, and the body weight of the rats was 230 - 250 g. According to the technical scheme of "Research on the Rat Animal Model of Vaginitis and Cervicitis" (Long Zijiang et al., 2005), a rat model of gynecological inflammation was prepared. According to the scheme of the aforementioned paper, each rat vagina was injected with phenol glue slurry at 0.01 ml / kg, and the injection was continuous for 3 days. Rats with red and swollen vaginal orifices and a large amount of purulent substances flowing out were selected as experimental rats.

[0056] Eighty experimental rats were selected and divided into eight groups, with 10 rats in each group. Among them, seven groups were respectively intragastrically administered the compositions of Examples 1 to 3 and Comparative Examples 1 to 4, and the remaining one model group was intragastrically administered an equal amount of sterile water. After continuous intragastric administration for 14 days and observation for 2 days, local radiographs of the female rats' vaginas were taken for observation.

[0057] Dosage:

[0058] The intake of astaxanthin for adults is 4 - 12 mg / d, calculated according to 12 mg / d. Astaxanthin oil contains 5% astaxanthin. To intake 120 mg of astaxanthin oil, with the adult body weight calculated as 60 kg, the intake of astaxanthin oil for adults is: 4 mg / kg BW.

[0059] For Gardenia jasminoides Ellis, according to the Chinese Pharmacopoeia 2020 Edition, the intake of crude drug for adults is 6 to 10 grams, with the adult body weight calculated as 60 kg. Calculated based on 10 g of the crude drug of Panax japonicus Torr., the water extraction of the 20:1 specification can obtain 500 mg of extract. Therefore, calculated according to the requirements of the pharmacopoeia, the daily intake of adults is: 8.33 mg / kg BW.

[0060] For Curcuma longa L., according to the Chinese Pharmacopoeia 2020 Edition, the intake of crude drug for adults is 3 to 10 grams, with the adult body weight calculated as 60 kg. Calculated based on 10 g of the crude drug of Panax japonicus Torr., the water extraction of the 20:1 specification can obtain 500 mg of extract. Therefore, calculated according to the requirements of the pharmacopoeia, the daily intake of adults is: 8.33 mg / kg BW.

[0061] For Portulaca oleracea L., according to the Chinese Pharmacopoeia 2020 Edition, the intake of crude drug for adults is 9 to 15 grams, with the adult body weight calculated as 60 kg. Calculated based on 15 g of the crude drug of Panax japonicus Torr., the water extraction of the 20:1 specification can obtain 750 mg of extract. Therefore, calculated according to the requirements of the pharmacopoeia, the daily intake of adults is 12.5 mg / kg BW.

[0062] Based on the astaxanthin oil in the composition (adult: 4 mg / kg BW), the human dosage was calculated according to the content of astaxanthin oil in each composition, and the mice were intragastrically administered according to this amount. Among them, the model control group was intragastrically administered the same volume of distilled water, and the cure criteria were as follows:

[0063] Recovery: No redness and swelling at the vaginal orifice, no purulent secretion.

[0064] Effective: There is mild swelling and redness at the vaginal orifice, with a small amount of purulent discharge.

[0065] Ineffective: There is obvious swelling and redness at the vaginal orifice, with a large amount of purulent discharge.

[0066] The curative effects were statistically analyzed according to the administration situations of each group, as shown in Table 1 below:

[0067] Table 1 Statistical table of the curative effects of the composition

[0068] Treatment Cured / Only Effective / Only Ineffective / Only Cure Rate / % Effective Rate% Example 1 10 0 0 100 100 Example 2 10 0 0 90 90 Example 3 10 0 0 100 100 Comparative Example 1 4 4 2 40 80 Comparative Example 2 3 5 3 30 80 Comparative Example 3 5 2 3 50 70 Comparative Example 4 2 3 5 20 50 Model Group 0 1 9 0 10

[0069] As can be seen from Table 1 above, the astaxanthin compositions provided in Embodiments 1 to 3 of the present invention have good curative effects on vaginitis and cervicitis, and Comparative Example 4 using astaxanthin alone also has a certain curative effect.

[0070] The preferred embodiments of the present invention have been described in detail above. However, the present invention is not limited thereto. Within the technical concept scope of the present invention, various simple modifications can be made to the technical solutions of the present invention, including any other suitable combination of each technical feature. These simple modifications and combinations should also be regarded as the content disclosed by the present invention and fall within the protection scope of the present invention.

Claims

1. An astaxanthin composition for preventing and treating vaginitis and cervicitis, characterized in that, The composition consists of the following components in parts by mass: 200 - 280 parts of astaxanthin oil, 40 - 60 parts of gardenia extract, 25 - 35 parts of turmeric extract, and 62 - 84 parts of purslane extract; the astaxanthin content in the astaxanthin oil is 5%, and the gardenia extract, turmeric extract, and purslane extract are all water extracts with a specification of 20:

1.

2. The astaxanthin composition for preventing and treating vaginitis and cervicitis according to claim 1, wherein, The composition consists of the following components in parts by mass: 240 parts of astaxanthin oil, 50 parts of gardenia extract, 30 parts of turmeric extract, and 73 parts of purslane extract.

3. The astaxanthin composition for preventing and treating vaginitis and cervicitis according to claim 1, characterized in that, The composition consists of the following components in parts by mass: 200 parts of astaxanthin oil, 40 parts of gardenia extract, 25 parts of turmeric extract, and 62 parts of purslane extract.

4. The astaxanthin composition for preventing and treating vaginitis and cervicitis according to claim 1, wherein The composition consists of the following components in parts by mass: 280 parts of astaxanthin oil, 60 parts of gardenia extract, 35 parts of turmeric extract, and 84 parts of purslane extract.

5. The preparation method of the astaxanthin composition for preventing and treating vaginitis and cervicitis according to claim 1, characterized in that: It includes the following steps: S1. Add 25 - 30 parts by mass of glycerol monocaprylate to 200 - 280 parts by mass of astaxanthin oil, and stir to emulsify it to obtain an astaxanthin oil emulsion. S2. Add 45 - 130 parts by mass of sodium carboxymethylcellulose and 35 - 55 parts by mass of β - cyclodextrin to the astaxanthin oil emulsion, and stir evenly to obtain a mixed slurry. S3. Spray - dry the mixed slurry obtained in step S2 to obtain astaxanthin powder. S4. Add 40 - 60 parts by mass of gardenia extract, 25 - 35 parts by mass of turmeric extract, 62 - 84 parts by mass of purslane extract, and 65 - 110 parts by mass of β - cyclodextrin to an appropriate amount of purified water, stir to dissolve, and then spray - dry the mixture to obtain a mixed powder. S5. Mix the astaxanthin powder obtained in step S3 and the mixed powder obtained in step S4 evenly to obtain the composition.

6. Use of the astaxanthin composition according to any one of claims 1 to 4 in the preparation of a drug for preventing and treating vaginitis and cervicitis.